Targeting EGFR Exon 20 Insertion Mutation in Non–small cell Lung Cancer: Amivantamab and Mobocertinib
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221098398
Abstract: Objective To evaluate clinical data regarding the use of amivantamab and mobocertinib for epidermal growth factor receptor (EGFR) exon 20 insertion mutation non–small cell lung cancer (NSCLC) and assess their potential impact on the care… read more here.
Keywords: exon insertion; egfr exon; insertion mutation; amivantamab mobocertinib ... See more keywords